Ascentage Pharma Group International (AAPG) Total Non-Current Liabilities (2023 - 2025)

Ascentage Pharma Group International (AAPG) has reported Total Non-Current Liabilities for 3 consecutive years, with $139.0 million the latest figure, recorded in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 15.16% year-over-year to $139.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $139.0 million (down 15.16% YoY) and the FY2025 annual result came in at $141.0 million, down 12.56% from the prior year.
• Total Non-Current Liabilities declined to $139.0 million in Q4 2025 per AAPG's latest filing, from $424.2 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for AAPG reached as high as $424.2 million in Q2 2025 and fell as low as $139.0 million in Q4 2025.
• A 3-year average of $233.7 million and a median of $185.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities retreated 21.11% — and 2025, when it slipped 15.16%.
• Year by year, Total Non-Current Liabilities stood at $207.7 million in 2023, then slipped by 21.11% to $163.9 million in 2024, then decreased by 15.16% to $139.0 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $139.0 million, $424.2 million, and $163.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.